DREAMM-20 Hints at a More Tolerable Path for BCMA-Targeted Therapy in Myeloma

(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) meeting, early data from the DREAMM-20 trial showed that the naked B-cell maturation antigen (BCMA)-targeted monoclonal antibody belantamab — without the cytotoxic…